Due Diligence
Support

Due diligence services are constructed for companies seeking investment or strategic partnering, and also for the investment community. Bracken offers an integrated approach to due diligence projects, as they may require scientific, regulatory, or medical evaluation, as well as financial, strategic, and business evaluation. The team is pleased to collaborate with other experts or own the process entirely.

A critical component of drug development success is accessing adequate resources, both intellectual and financial, to bring a product from discovery to market. Financial institutions play a crucial role in successful drug development. These organizations are afforded numerous investment opportunities within healthcare for evaluation. Due diligence is an essential aspect of the investor’s decision-making process.

Bracken regularly undertakes due diligence at all stages of product development, and services include:

1. Development of business plans - helping guide nascent technology or compounds forward by developing the roadmap that integrates scientific, medical, regulatory, business, financial and marketing plans for success.
2. Preparing investment packages for prospective investors so that companies can raise that critical next round of funding.
3. Gap analyses: Business, intellectual property protection (IP), regulatory, competitive landscape, estimated market size, etc.
4. High-level SWOT analysis of products and/or technology under consideration.

Successful drug development is a complex and costly process. Insightful integration of sound science and financial resources is essential. Our experienced biopharma consultants are qualified to assist both the development company and its financial partners throughout the entire process – helping to reduce investor and partner risk, while optimizing business strategy for on-time and on-budget product delivery.

• High-level SWOT analysis of multiple opportunities
• In-depth analysis of companies under serious investment consideration
• Full regulatory gap analysis
• Risk assessment and mitigation proposals
• Competitive landscape analysis that looks at current market competition, as well as a complete analysis of drugs in development, their stages and disposition